The H1 was first launched in the year 1992 and was owned by many popular and prominent personalities. The Hummer H1 laid the foundation of the Hummer Civil Production unit. Hummer H1: The Hummer H1 is four-wheel drive vehicle which was inspired from the US army’s Humvees.Hummer has produced three SUVs till date which include. SUV’s: With the iconic Box type body and bulky appearance, the Hummer SUVs make a completely different style statement.Hummer’s production line includes SUVs, Offroad Racing and Stretch Limousines. AM General first named the brand ‘Humvees’ which later changed to ‘Hummer in the year 1992 as the brand opened for the civil market. In the year 1979, when the US army was in need of High Mobility Multi-Purpose Wheeled Vehicle that would enable smooth transit for the army, there were four companies that proposed to offer vehicles for this contract, but AM General got the contract and presented the first prototype in the year 1982. Blood cell count: White blood count (WBC) >= 2000/μL;Neutrophil count >= 1500/μL;Platelets >= 100 x 103/μL;Hemoglobin >= 9.Hummer is an automobile manufacturing company that is known for the production of SUVs and Trucks.Patients with other chronic AEs are in the investigator's judgement.2 weeks of wash-out time after completion of targeted therapy with related adverse events (AE) on baseline (4 weeks for Bevacizumab).>= 14 days after completion of Temozolomide or other chemotherapy.>= 6 weeks after completion of nitrourea chemotherapy.>= 8 weeks after completion of front-line radiation therapy.Eastern Cooperative Oncology Group (ECOG) =0 or 1 (need to be confirmed before intratumoral or intracerebroventricular injection).Suitable for the surgery of the placement of the Ommaya catheter.Relapsed/refractory disease confirmed by radiographic evidence after standard therapy.Clinical Pathology confirms B7-H3 positive tumor expression by immunohistochemistry (IHC) at the initial tumor presentation or recurrent disease (H-score >= 50).Histologically confirmed diagnosis of World Health Organization (WHO) classification grade IV glioblastoma (GBM).Documented informed consent of the participant and/or legally authorized representative.Patients may receive additional CAR-T cycles at the discretion of the principal investigator and oncologist. Temozolomide treatment in the cycle of CAR-T injections will be stopped and resumed next cycle. The CAR-T injections occur in between Temozolomide (TMZ) cycles. 3 injections of CAR-T are planned at two different doses with 1-2 weeks intervals. CAR-T cells are expanded ex vivo and infused back to patients via intratumoral or intracerebroventricular injection through an Ommaya catheter. Patients autologous T cells are activated and transduced with retrovirus containing B7-H3 CAR. To access the pharmacokinetics and pharmacodynamics of B7-H3 CAR-T in between Temozolomide cycles.
![h3 car h3 car](https://cdne.carbuzz.com/img.lotlinx.com/vdn/27815/hummer_h3_2006_5GTDN136668281667_27815_2114221057.jpg)
To compare the overall survival (OS) and progression-free survival (PFS) of R/R GBM patients treated with B7-H3 CAR-T in between Temozolomide cycles to the historical Temozolomide data.To evaluate the safety and tolerability intratumoral/intracerebroventricular injection of B7-H3 CAR-T when used in between Temozolomide cycles.The investigators constructed a retroviral vector encoding a chimeric antigen receptor (CAR) targeting B7-H3, which can mediate CAR transfer into patient T cells with high efficiency.Therefore, it is an attractive GBM target for CAR-T therapy B7-H3 is not expressed in normal tissues especially not in central nervous system.B7-H3 is expressed in 70% of patients with glioblastoma.Why Should I Register and Submit Results?.